Correction: Association of endocrine immune-related adverse events with progression-free survival in advanced non-small cell lung cancer treated with PD-1/PD-L1 inhibitors with or without anlotinib.

Furong Sun, Yuzhu Gao, Xiaoyan Zheng, Jie Hua, Shouzhen Liu, Dong Cao, Jianping Zhou

Abstract readPublished Erratum

In one paragraph

Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it

0cells of the map it votes in

0citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

Erratum for
Association of endocrine immune-related adverse events with progression-free survival in advanced non-small cell lung cancer treated with PD-1/PD-L1 inhibitors with or without anlotinib.2026

5 · Who and what money

Authors and funding

7 authors.

Furong Sun *Department of Respiratory and Critical Care Medicine, Zhoushan Branch, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Zhoushan, China.

Yuzhu Gao *School of Medical Information Engineering, Guangzhou University of Chinese Medicine, Guangzhou, China.

Xiaoyan ZhengDepartment of Respiratory and Critical Care Medicine, Zhoushan Branch, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Zhoushan, China.

Jie HuaDepartment of Respiratory and Critical Care Medicine, Zhoushan Branch, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Zhoushan, China.

Shouzhen LiuDepartment of Respiratory and Critical Care Medicine, Zhoushan Branch, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Zhoushan, China.

Dong CaoSchool of Medical Information Engineering, Guangzhou University of Chinese Medicine, Guangzhou, China.

Jianping ZhouDepartment of Respiratory and Critical Care Medicine, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

[This corrects the article DOI: 10.3389/fonc.2026.1701750.].

Indexed as

anlotinibendocrine immune-related adverse eventsnon-small-cell lung cancerPD-1/PD-L1 inhibitorsprogression-free survival

Identifiers

PMID42100392

DOI10.3389/fonc.2026.1847088

PMCPMC13147503

What OpenQuestion holds

Textmetadata

LicenceCC BY

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.